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Edited by Michael R. BubbAbstract A peptide with a sequence identical to rat thymosin
b(Tb)15 was reported to be upregulated in human prostate can-
cer. However, in this report we provide evidence that TbNB, ini-
tially identiﬁed in human neuroblastoma, is the only Tb isoform
upregulated in human prostate cancer and that the Tb15
sequence is not present herein. In addition, we demonstrate that
human TbNB has a higher aﬃnity for actin in comparison to Tb4
and promotes cell migration. In combination, this experimentally
validates TbNB as functional homologue of rat Tb15 in the
human organism and clariﬁes the current composition of the
human Tb family.
 2007 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Cell migration1. Introduction
b-Thymosins (Tbs) are actin sequestering proteins: they inhi-
bit incorporation of actin monomers (G-actin) in actin ﬁla-
ments (F-actin) by binding the monomers. In cells, this Tb
bound G-actin reserve is available for rapid actin polymeriza-
tion. This function may underlie the role of Tb in cell migra-
tion and the observed correlation between tumour
progression and Tb expression levels [1–3]. Besides its role in
cell migration, Tb is implicated in multiple other cellular func-
tions that are deregulated in tumour cells (reviewed in [4]).
The Tb polypeptides are highly conserved, except for their
extreme C-termini. Four human Tb isoforms have been re-
ported (Fig. 1A). Thymosin b4 (Tb4) is the most abundant iso-
form in human tissue, followed by thymosin b10 (Tb10). A
third Tb was described to be speciﬁcally expressed in neuro-
blastoma tissue, hence its name thymosin b neuroblastoma
(TbNB) [5]. In the same period, Bao et al. observed that rat
thymosin b15 (Tb15) is upregulated in highly metastatic versusAbbreviation: Tb, thymosine b
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doi:10.1016/j.febslet.2007.09.003poorly metastatic rat prostate cell lines [3]. Using an antibody
raised against this rat isoform, they obtained a signal in malig-
nant human prostate cancer, which was almost absent in be-
nign human tissue. This upregulated human Tb was claimed
to have an identical peptide sequence as rat Tb15. By now,
the use of the anti-rat Tb15 antibody has turned out promising
for early identiﬁcation of prostate cancer patients at high risk
of recurrence [6]. Studies using the rat Tb15 sequence show
that elevated levels of Tb15 promote cell migration [3], neurite
branching [7], survival of motoneurons [8] and induction of
angiogenesis [9].
In this report, we provide proﬁling as well as biochemical
data which clearly prove that in the human organism the true
functional homologue of rat Tb15 is TbNB, initially identiﬁed
in neuroblastoma. We detected TbNB in several human cancer
cell lines and in prostate cancer tissue samples, but herein ob-
served no Tb15. We state that a peptide with the sequence of
rat Tb15 is not present in human cells, and that the third
human Tb isoform next to Tb4 and Tb10 is TbNB, which is
equivalent to rat Tb15. We describe that TbNB has a higher
aﬃnity for actin in comparison to Tb4, similar to rat Tb15
and show that human TbNB overexpression promotes cell
migration. Our data permit to evaluate more correctly previ-
ous studies using the rat Tb15 peptide sequence in the context
of human cancer biology.2. Materials and methods
2.1. Protein and peptides
Rabbit skeletal muscle actin was prepared [10] and stored in G-buf-
fer (5 mM Tris–HCl pH 7.7, 0.1 mM CaCl2, 0.2 mM ATP, 0.2 mM
DTT). Actin was labelled with N-pyrenyliodoacetamide [11]. N-termi-
nally acetylated Tb4 and TbNB were chemically synthesized on a mod-
el 431A peptide synthesizer (Applied Biosystems Inc., Foster City, CA)
using standard Fmoc-chemistry. The correct mass of cleaved and re-
verse-phase HPLC puriﬁed peptides was conﬁrmed on a MS-Q-Tof1
(Micromass).2.2. Tb expression constructs
Human Tb4 and TbNB were ampliﬁed from a human foetal kidney
cDNA library (Stratagene) and cloned into pEG/YFP-C1 and pEG/
YFP-N1 mammalian expression vectors (Clontech, BD Biosciences)
to allow expression of Tb, N- and C-terminally fused to eGFP (for
Tb4) or eYFP (for TbNB) respectively. The K18E mutation was intro-
duced using QuikChange mutagenesis (Stratagene).blished by Elsevier B.V. All rights reserved.
Fig. 1. Human TbNB is widespread, whereas Tb15 is not present in human cells. (A) Multiple sequence alignment of human (bold) and rat Tb
isoforms, and percentage sequence similarity. Peptide sequences of human Tb isoforms Tb4, Tb10 and TbNB (GenBank Accessions NP_066932,
NP_066926, BAA11556) and of rat Tb isoforms Tb4, Tb10 and Tb15 (GenBank Accessions NP_112398, NP_067084, AAB37101) were aligned using
ClustalW (1.83) (www.ebi.ac.uk/clustalw). In the consensus sequence ‘*’ stands for identical, ‘:’ for conserved and ‘.’ for semi-conserved residues. Hs,
Homo sapiens. Rn, Rattus norvegicus. (B) QRT-PCR of Tb isoforms in human cell lines. Normalized transcript levels of Tb4, Tb10, TbNB and Tb15
are plotted. Tb4 value in PC3 cells is set to one. n.d., not detected. (C) tBLASTn search of TbNB in human EST cDNA library
(www.ncbi.nlm.nih.gov/BLAST). Sequences originating from the same cDNA template or derived from a mix of foetal, tumourigenic or normal
adult cDNA were omitted from speciﬁc hits obtained on June 24th 2007.
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MDA-MB-231, GF-PAC, LNM35, HT-115 and NIH3T3 cells were
cultured in DMEM with GlutaMAX-I (Gibco) supplemented with
10% heat inactivated foetal bovine serum (Gibco) and 1% penicillin–
streptomycin (Gibco). RPMI 1640 (Gibo) and DMEM/F-12 (Gibco)
were used for PC3 and MCF7/AZ cells, respectively. Medium of
HT-115 cells was supplemented with 0.01% MEM non-essential amino
acids solution (Gibco). All cells were cultured at 37 C in 5% CO2. The
cell lines were a gift of Prof. Bracke (University Hospital of Ghent,
Belgium). MDA-MB-231 cells were provided by Prof. Berx (VIB
Department of Molecular Biomedical Research, University of Ghent).
We transfected NIH3T3 cells using FuGene6 Reagent (Roche).2.4. qRT-PCR
Total RNA of prostate tissue samples (as described [12]) was ex-
tracted using caesium chloride method. Total RNA from approxi-
mately 1 · 107 ﬂash frozen human cancer cell line cells was isolated
using RNeasy Midi (Qiagen) and DNaseI treated. cDNA was prepared
from total RNA with the iScript cDNA Synthesis Kit (Bio-Rad).
Target speciﬁc primers were designed using Lightcycler Probe Design
Software 2.0 (Roche) and synthesized by Proligo (Sigma) based on
GenBank Accessions NM_021109, NM_021103, D82345 and
AX645184 for Tb4, Tb10, TbNB and Tb15 reported in Homo sapiens,
respectively (Supplementary Table S1). In silico validation of primers
was done by blasting the primer set against the human non-redundant
database (NCBI). All qRT-PCR reactions were performed on a Light-
cycler 2.0 (Roche) using Fast start SYBR Green master mix (Roche).
Human GADPH was used as housekeeping gene. Relative concentra-tion ratios (target versus housekeeping gene) were calculated using
LightCycler 2.0 software (Roche) taking into account primer set spe-
ciﬁc eﬃciencies.
2.5. Actin binding assays
G-actin (12 lM) in G-buﬀer was mixed with Tb4 or TbNB at vari-
ous molar ratios and incubated for 20 min at room temperature before
loading on native polyacrylamide gels as in [13].
For actin polymerization assays we incubated Tb (2.5–5–10 lM)
with G-actin (5 lM, 10% pyrene labelled) in G-buﬀer for 10 min at
room temperature. Polymerization was initiated by addition of salt
(100 mM KCl, 1 mM MgCl2). The increase in ﬂuorescence was moni-
tored as a function of time at room temperature using excitation and
emission wavelengths of 365 nm and 388 nm respectively (ﬂuorimeter
F-4500, Hitachi).
Dissociation constant of the Tb–G-actin complex was determined as
described [13]. Brieﬂy, samples containing 1 lM F-actin and increasing
amounts of Tb4 or TbNB in polymerizing buﬀer (G-buﬀer + 100 mM
KCl, 1 mM MgCl2) were incubated overnight at room temperature to
allow the reaction to reach steady state. Sequestering by Tb results in a
decreased ﬂuorescence signal. From this decrease a Kd is calculated
[13]. The critical monomer concentration of actin (0.16 lM) was
derived from a parallel experiment [13].
2.6. Phalloidin staining
Cells were washed twice with PBS (0.1 M sodium phosphate buﬀer,
pH 7.5), ﬁxed with 4% paraformaldehyde for 20 min and permeabili-
zed with 0.1% Triton X-100 for 1 min. After washing with PBS and
S. Dhaese et al. / FEBS Letters 581 (2007) 4809–4815 481110 min incubation with blocking agent (2% bovine serum albumin),
Alexa Fluor594 phalloidin (Molecular Probes) was added for
30 min. Stained cells were imaged using an Olympus IX71 inverted
ﬂuorescence microscope equipped with a monochrome Spot-RT digital
camera (Progress Control) and AnalySIS software (Soft Imaging Sys-
tem, GmbH).
2.7. Migration assay, adapted to transiently transfected ﬂuorescent cells
Twenty-four hours after transfection, NIH3T3 cells were serum
starved for 24 h. 50000 cells in 700 ml serum free medium were seeded
on the 8 lmpore membrane of 12-well transwells (BDBiosciences). The
lower compartment was ﬁlled with 1.7 ml medium supplemented with
20% foetal bovine serum (Gibco). Migration through the membrane
was scored after 17 h. Phase-contrast as well as ﬂuorescent images
(20· magniﬁcation) at one central and three peripheral positions were
taken in order to determine the percentage of ﬂuorescent cells in the to-
tal cell population by manually counting cells. After removal of cells in
the upper compartment, the remaining migrated cells on the membrane
were analogously processed. The relative percentage of ﬂuorescent cells
in the migrated versus total population is a measure to determine
whether ﬂuorescent cells migrate with lower, higher or similar eﬃciency
in comparison to non-ﬂuorescent cells. Means and standard deviations
were calculated from three independent experiments.3. Results and discussion
3.1. TbNB is widespread, whereas Tb15 is not present in human
cells
To determine the relative expression levels of Tb isoforms
(Fig. 1A) in human cancer cell lines, we used qRT-PCR with
probes speciﬁc for Tb4, Tb10, TbNB and Tb15 (Fig. 1B) (Sup-
plementary Table S1). Tb4 was the major Tb transcript present
in all cell lines tested. Tb10 was detected at a lower level rela-
tive to Tb4, except in lung adenocarcinoma LNM35 cells in
which we found similar amounts of both forms. Although
TbNB was initially reported to be neuroblastoma speciﬁc, we
found TbNB mRNA expression at comparable levels as
Tb10 mRNA in pancreatic adenocarcinoma GF-PAC cells
and breast adenocarcinoma MDA-MB-231 and MCF7/AZ
cells. Relatively low levels were found in LNM35 cells. In pros-
tate carcinoma PC3 cells, the amount of TbNB mRNA even
equalled that of Tb4 mRNA, making it the second most abun-Fig. 2. Human TbNB is upregulated in prostate tumour samples. QRT-PCR
ratios of Tb4, Tb10 and TbNB were measured in prostate tumour samples (T
Tb level in tumour versus normal samples ((TN)/N) is shown as percenta
Gleason score (Gs) is indicated for the tumour of each patient (1–4).dant Tb transcript in these cells. Other groups detected TbNB
peptide in human thrombocytes [14] and TbNB transcript in a
larynx carcinoma cell line [15]. A tBLASTn search in the
human expressed sequence tag (EST) database (www.ncbi.
nlm.nih.gov/BLAST) further demonstrates that TbNB is
expressed in a wide variety of tissues (Fig. 1C), ranging from
normal adult tissue to foetal and tumourigenic tissue.
Remarkably we could not amplify the fourth reported hu-
man Tb isoform, Tb15, from any of the human cancer cell lines
tested, although we obtained a speciﬁc product when using a
rat cell line as template (data not shown). Even human pros-
tate cancer PC3 cells did not contain detectable Tb15 mRNA.
This contrasts with the relatively high Tb15 mRNA level re-
ported by Bao et al. in these cells [16]. Moreover, we could
not ﬁnd any human EST for Tb15, nor did we retrieve any spe-
ciﬁc hit by a tBLASTn search of the complete human genome
(ENSEMBL, www.ensembl.org). In addition, others failed to
detect the Tb15 peptide in human breast adenocarcinoma
MCF7 cells using highly sensitive techniques [17].
In conclusion, our own data together with published data
[14,15,17] indicate that TbNB expression is less restricted than
initially postulated, whereas the Tb15 transcript with sequence
as reported [3], does not appear to be present in the human
transcriptome. Using an antibody raised against the rat Tb15
peptide, Bao et al. showed that a Tb isoform diﬀerent from
Tb4 and Tb10 is upregulated in human prostate cancer. After
isolating and sequencing, this human Tb was claimed to have
an identical amino acid sequence as rat Tb15 [3]. However,
based on our proﬁling study in several human cancer cell lines,
our in silico database mining and data described below, we
provide experimental evidence that this Tb is in fact TbNB
and that TbNB is the human functional homologue of rat
Tb15.3.2. TbNB mRNA is upregulated in human prostate cancer
tissue samples versus matched healthy samples
If human TbNB is equivalent to rat Tb15, then its expression
should be increased in prostate cancer tissue. We screened hu-
man biopsies containing prostate cancer of various Gleasonof Tb isoforms in human prostate tissue samples. Normalized mRNA
) and in matched healthy normal prostate samples (N). The change in
ge increase. Tb15 was tested but not detected in any of the samples.
4812 S. Dhaese et al. / FEBS Letters 581 (2007) 4809–4815scores for Tb expression using sensitive qRT-PCR. In line with
the relatively high expression level of TbNB mRNA and the
absence of Tb15 mRNA in prostate cancer PC3 cells
(Fig. 1B), TbNB is indeed upregulated in human prostate can-
cer tissue samples versus matched healthy prostate samples
(Fig. 2), whereas we found no evidence for a Tb15 transcript.
For Tb4 or Tb10 we did not observe a consistent trend in
altered expression levels. The samples used here are whole
prostate tissue samples, not solely composed of tumour cells.Fig. 3. TbNB is a stronger actin sequestering peptide than Tb4. (A) Kinetics o
by Tb4. Kinetics of actin polymerization after addition of (1) 2.5 lM, (2) 5 lM
in real time by detecting ﬂuorescence as a measure for the amount of F-actin f
complex displays higher electrophoretic mobility than G-actin (G-A). (C) Ste
content was determined at equilibrium and plotted in function of Tb concent
derived: 2 lM and 8 lM, respectively (actin critical monomer concentrationTherefore, in our experiment, basal TbNB expression may
mask a correlation with tumour grade. Despite this we still
show a clear upregulation of TbNB mRNA in tumour versus
healthy samples of the same patient.
We conclude that a Tb with the human TbNB sequence
and not the rat Tb15 sequence is upregulated in human pros-
tate cancer. During the preparation of our manuscript, the
group of Zetter also suggested that TbNB is the human iso-
form of rat Tb15 based on in silico searches, yet they did notf actin polymerization are slowed down by TbNB and to a lesser extent
and (3) 10 lMTb to 5 lM actin (10% pyrene labelled) were monitored
ormed. (B) G-actin binding of TbNB and Tb4. The actin-Tb (Tb–G-A)
ady state actin polymerization is inhibited by TbNB and Tb4. F-actin
ration. From the slope the Kd for Tb4 and TbNB-actin complexes was
= 0.16 lM).
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similar eﬀects [18]. Since they extrapolated actin binding
properties and cell biological functions of TbNB from re-Fig. 4. TbNB enhances cell migration. (A) Transient Tb4 and TbNB overex
phalloidin signal (visualising cellular F-actin) in NIH3T3 ﬁbroblasts are show
and TbNB overexpression in NIH3T3 ﬁbroblasts enhances cell migration. Fro
in the migrated (%Mﬂuo) cell population, the increase in percentage o
((%Mﬂuo%Tﬂuo)/ %Tﬂuo). Error bars represent standard deviations of threeports in which the rat Tb15 sequence was used, it is neces-
sary to investigate biochemical and cellular features of
human TbNB.pression in NIH3T3 aﬀects F-actin cytoskeleton. GFP/YPF signal and
n. Upper panel: N-fusions, lower panel: C-fusions. (B) Transient Tb4
m the observed percentage of ﬂuorescent cells in the total (%Tﬂuo) and
f ﬂuorescent cells in the migrated population was calculated as
independent experiments.
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than Tb4, as is rat Tb15
The rat and human Tb family thus both comprise three iso-
forms. Rat and human Tb4 and Tb10 homologues are identi-
cal at the amino acid level, rat Tb15 and its human homologue
TbNB are less well conserved: human TbNB has 88% sequence
similarity to rat Tb15 (Fig. 1A). The main diﬀerences are situ-
ated at the C-terminal ends. The role of the C-terminus of Tb
can be extracted from current structural models of the Tb4-ac-
tin complex. Tb4 has an extended conformation with its amino
and carboxy termini located at opposite sides of the actin
monomer [19–21]. Sterical hindrance thus explains why ac-
tin-Tb complexes do not incorporate into actin ﬁlaments.
There is some discussion about the position of the C-terminal
half of Tb4 in the Tb4-actin complex and the contacts made by
the extreme C-terminal residues are still unknown [20,21]. Not-
withstanding, it is evident that sequence diﬀerences in this re-
gion modulate actin binding: truncation of Tb4’s C-terminal
13 amino acids severely decreases actin binding aﬃnity [22],
even deletion of the last two amino acids of Tb10 leads to a
slightly higher dissociation constant [23]. For rat Tb15 it is
shown that the C-terminus strongly contributes to a higher ac-
tin binding aﬃnity using chimerical peptides of Tb15 and Tb4
in which C-termini were exchanged [24]. The C-terminus of hu-
man TbNB is more similar to the one of rat Tb15 than to
Tb4’s, though still contains signiﬁcant diﬀerences (Cys40-
Tyr40, Val41-Asn41, Thr43-Arg43).
Using diﬀerent assays, we show that human TbNB has a
higher actin binding aﬃnity than Tb4. The kinetics of salt in-
duced actin polymerization are more strongly inﬂuenced by
TbNB than by Tb4; lower concentrations of TbNB are re-
quired to exert similar inhibitory eﬀects on nucleation and
elongation (Fig. 3A). This is also evidenced by the fact that
at molar ratios of 2:1 Tb:actin, TbNB almost fully complexes
all actin present, whereas using Tb4 a clear band of non-com-
plexed monomeric actin can still be distinguished in non-dena-
turing gels (Fig. 3B). We determined equilibrium dissociation
constants of 2 lM and 8 lM for TbNB and Tb4-actin com-
plexes respectively (Fig. 3C). Similarly, Eadie et al. reported
a lower dissociation constant for rat Tb15 in comparison to
Tb4 (2.0 lM and 4.8 lM, respectively) [24].
The fact that both human TbNB and rat Tb15 are stronger
actin binding sequestering proteins than Tb4 supports our
assumption that TbNB is the true functional human homo-
logue of rat Tb15.
3.4. Human TbNB promotes cell migration, as does rat Tb15
We further compared TbNB function by investigating the ef-
fect of overexpression of ﬂuorescent Tb fusions in ﬁbroblast
cells. To rule out bias of the results by fusing Tb to eGFP
(or variant), we expressed C-terminal as well as N-terminal
fusions. The functionality of Tb fusions was shown by the
strongly reduced F-actin content in cells highly expressing
Tb fusions (Fig. 4A). Mainly cytosolic F-actin is aﬀected,
whereas cortical F-actin is still present. This is not the case
for eGFP transfected cells, neither for cells transfected with a
Tb mutant defective in actin binding: Tb4 K18E [13].
It has been reported that upon silencing of Tb15, serum in-
duced migration of rat prostate cancer cells was signiﬁcantly
decreased [3]. Using the same migration assay, we observed
an increase in migration upon overexpression of TbNB in ser-um stimulated ﬁbroblast cells. Fig. 4B shows that Tb over-
expressing cells gain advantage to migrate, and this eﬀect is
stronger in case of TbNB than of Tb4. Since Tb4 K18E loses
this advantage, the observed eﬀect is actin binding dependent.
A much higher migration eﬃciency is observed when
expressing TbNB N-terminal versus C-terminal fusions. A
non-fused C-terminus may be needed to fully exhibit the high-
er actin binding aﬃnity of TbNB in comparison to that of Tb4;
however, one needs to be careful when associating strength of
Tb eﬀects with strength of actin binding, because in cells a
higher local concentration could easily compensate for a lower
actin binding aﬃnity. Nonetheless, we show that TbNB has a
migration promoting eﬀect in analogy as was found for rat
Tb15.
In conclusion, our proﬁling data in combination with bio-
chemical and cell biological approaches all indicate that TbNB
is the true functional human homologue of rat Tb15. We dem-
onstrate speciﬁc upregulation of this isoform in human pros-
tate cancer. The anti-rat Tb15 antibody previously used to
identify this upregulation was shown to have low reactivity
versus human TbNB [6]. Although it could still discriminate
patients at high versus low risk of recurrence [6,25], our data
suggest that development and use of an antibody that more
speciﬁcally and sensitively recognizes TbNB, might greatly im-
prove the ability to identify prostate tumour cancer patients
with a risk of progression. Also, future research using the cor-
rect human Tb isoform will shed light on the advantage pros-
tate and other tumour cells gain by upregulating TbNB.
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